An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer.
Carol Aghajanian
No relevant relationships to disclose
Stephanie V. Blank
No relevant relationships to disclose
Barbara Ann Goff
Honoraria - Lilly
Patricia Lynn Judson
No relevant relationships to disclose
Lawrence R. Nycum
No relevant relationships to disclose
Mika A. Sovak
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Jing Yi
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Amreen Husain
Employment or Leadership Position - Genentech
Stock Ownership - Roche